Exercise and white matter hyperintensities: a randomized clinical trial.
14 affiliations
- 1Department of Health, Kinesiology, and Applied Physiology, Faculty of Arts and Science, Concordia University, Montréal, Canada H4B 1R6.
- 2Department of Physical Therapy, Faculty of Medicine, University of British Columbia, Vancouver, Canada V6T 1Z3.
- 3Djavad Mowafaghian Centre for Brain Health, Faculty of Medicine, University of British Columbia, Vancouver, Canada V6T 2B5.
- 4Centre for Aging SMART at Vancouver Coastal Health, Vancouver Coastal Health Research Institute, Vancouver, Canada V5Z 1M9.
- 5School of Biomedical Engineering, University of British Columbia, Vancouver, Canada V6T 1Z3.
- 6Department of Radiology, Faculty of Medicine, University of British Columbia, Vancouver, Canada V6T 1Z3.
- 7Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia 12372.
- 8Division of Geriatric Medicine, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver Canada V6T 1Z3.
- 9International Collaboration on Repair Discoveries, Blusson Spinal Cord Centre, Vancouver General Hospital, Vancouver Canada V5Z 1M9.
- 10Hotchkiss Brain Institute, University of Calgary, Calgary, Canada T2N 4N1.
- 11Faculty of Kinesiology, University of Calgary, Calgary, Canada T2N 1N4.
- 12Department of Rehabilitation Sciences, Faculty of Health and Social Sciences, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong, China.
- 13Division of Neurology, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, Canada V6T 1Z3.
- 14Vancouver Stroke Program, University of British Columbia, Vancouver, Canada V6T 1Z3.
Abstract
Subcortical vascular cognitive impairment (SVCI) is a risk factor for dementia. White matter hyperintensity (WMH) lesions are considered a hallmark of SVCI. We investigated the impact of progressive resistance exercise training (RT) on WMH in individuals with SVCI. This 12-month, single-blinded, proof-of-concept randomized clinical trial involved 89 community-dwelling individuals aged 55 years or older living with SVCI. Participants were randomized (1:1 ratio) to twice-weekly (60 min/day) RT (n = 44) or a balance and tone (BAT, n = 45) control intervention. Whole-brain and region-specific WMH volumes were measured using T₂- and proton density-weighted magnetic resonance imaging. Group differences in the 12-month change in WMH from baseline were determined via analysis of covariance, adjusting for baseline WMH, intracranial volume, age, sex and training format (remote versus in-person). Exploratory analyses tested associations between changes in WMH and changes in growth factors. Participants were mostly females (n = 58, 65.17%) with an average of 74.50 (SD 5.71) years. There were no differences between groups in whole-brain WMH volume after 12 months [estimated mean difference (95% CI): -0.016 (-0.052 to 0.019) log-transformed cm³, P = 0.364]. Region-specific analysis showed main effects of training on WMH volume in the temporal lobe [-0.115 (-0.207 to -0.023), P = 0.015] and splenium of the corpus callosum [-0.120 (-0.215 to -0.025), P = 0.014], favouring the RT group. There was a significant group-by-sex interaction, indicating that intervention effects varied by sex [estimated mean difference-of-differences (95% CI) = -0.093 (-0.170 to -0.016), P = 0.019]. Post hoc contrasts showed that RT (versus BAT) significantly reduced whole-brain WMH volume in female [-0.049 (-0.093 to -0.005), P = 0.029] but not male [0.044 (-0.017 to 0.105), P = 0.152] participants. Exploratory analysis showed that increasing levels of vascular endothelial growth factor [standardized β (95% CI) = -0.503 (-0.838 to -0.167), P = 0.004] were associated with a reduction in whole-brain WMH volume. No associations between insulin-like growth factor 1 and WMH volumes were found (all P > 0.05). Based on these findings, we conclude that progressive RT may reduce WMH progression in community-dwelling individuals living with SVCI. This trial is registered with ClinicalTrials.gov, number NCT02669394; submitted for registration on 1 February 2016; the first patient enrolment was on 26 May 2016.
Related
- Impact of White Matter Hyperintensities on Reperfusion Injury and Clinical Outcome After Successful Recanalization
- Physical exercise increases the NODDI-derived neurite density index across white matter tracts in healthy older adults: results from the FIT4BRAIN randomized controlled trial
- Lower fibrinogen and fibrinogen-to-albumin ratio in migraine with white matter hyperintensities: implications for microvascular vulnerability.
- White matter hyperintensities and amyloid pathology in cognitively unimpaired aging: topographical, microstructural, and network-level evidence
- A simplified Fazekas scale for efficient assessment of white matter hyperintensities.
BibTeX
@article{silva2026exercise,
title = {{Exercise and white matter hyperintensities: a randomized clinical trial.}},
author = {Nárlon C Boa Sorte Silva and Roger C Tam and Walid A Alkeridy and Kevin Lam and Elizabeth Dao and Cindy K Barha and Ryan S Falck and Chun Liang Hsu and Ging-Yuek Robin Hsiung and Ken M Madden and Thalia S Field and Teresa Liu-Ambrose},
journal = {Brain communications},
year = {2026},
month = oct,
doi = {10.1093/braincomms/fcag381},
url = {https://europepmc.org/article/MED/42948654},
note = {CC BY},
}
RIS
TY - JOUR
TI - Exercise and white matter hyperintensities: a randomized clinical trial.
AU - Nárlon C Boa Sorte Silva
AU - Roger C Tam
AU - Walid A Alkeridy
AU - Kevin Lam
AU - Elizabeth Dao
AU - Cindy K Barha
AU - Ryan S Falck
AU - Chun Liang Hsu
AU - Ging-Yuek Robin Hsiung
AU - Ken M Madden
AU - Thalia S Field
AU - Teresa Liu-Ambrose
PY - 2026
DA - 2026/10/08
JO - Brain communications
DO - 10.1093/braincomms/fcag381
UR - https://europepmc.org/article/MED/42948654
AB - Subcortical vascular cognitive impairment (SVCI) is a risk factor for dementia. White matter hyperintensity (WMH) lesions are considered a hallmark of SVCI. We investigated the impact of progressive resistance exercise training (RT) on WMH in individuals with SVCI. This 12-month, single-blinded, proof-of-concept randomized clinical trial involved 89 community-dwelling individuals aged 55 years or older living with SVCI. Participants were randomized (1:1 ratio) to twice-weekly (60 min/day) RT (n = 44) or a balance and tone (BAT, n = 45) control intervention. Whole-brain and region-specific WMH volumes were measured using T₂- and proton density-weighted magnetic resonance imaging. Group differences in the 12-month change in WMH from baseline were determined via analysis of covariance, adjusting for baseline WMH, intracranial volume, age, sex and training format (remote versus in-person). Exploratory analyses tested associations between changes in WMH and changes in growth factors. Participants were mostly females (n = 58, 65.17%) with an average of 74.50 (SD 5.71) years. There were no differences between groups in whole-brain WMH volume after 12 months [estimated mean difference (95% CI): -0.016 (-0.052 to 0.019) log-transformed cm³, P = 0.364]. Region-specific analysis showed main effects of training on WMH volume in the temporal lobe [-0.115 (-0.207 to -0.023), P = 0.015] and splenium of the corpus callosum [-0.120 (-0.215 to -0.025), P = 0.014], favouring the RT group. There was a significant group-by-sex interaction, indicating that intervention effects varied by sex [estimated mean difference-of-differences (95% CI) = -0.093 (-0.170 to -0.016), P = 0.019]. Post hoc contrasts showed that RT (versus BAT) significantly reduced whole-brain WMH volume in female [-0.049 (-0.093 to -0.005), P = 0.029] but not male [0.044 (-0.017 to 0.105), P = 0.152] participants. Exploratory analysis showed that increasing levels of vascular endothelial growth factor [standardized β (95% CI) = -0.503 (-0.838 to -0.167), P = 0.004] were associated with a reduction in whole-brain WMH volume. No associations between insulin-like growth factor 1 and WMH volumes were found (all P > 0.05). Based on these findings, we conclude that progressive RT may reduce WMH progression in community-dwelling individuals living with SVCI. This trial is registered with ClinicalTrials.gov, number NCT02669394; submitted for registration on 1 February 2016; the first patient enrolment was on 26 May 2016.
SN - 2632-1297
ER -